Frankfurt
13.08.26 | 09:55
4,075 Euro
+4,62 % +0,180
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | PolyPid Ltd. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| Mi | PolyPid GAAP EPS of -$0.35 beats by $0.03 | 5 | Seeking Alpha | ||
| Mi | PolyPid Ltd.: PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results | 905 | GlobeNewswire (Europe) | FDA Accepted D-PLEX100 NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance Exclusive U.S. and Canada Commercialization... ► Artikel lesen | |
| POLYPID Aktie jetzt für 0€ handeln | |||||
| Mi | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 30.07. | PolyPid Ltd.: PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026 | 7 | GlobeNewswire (USA) | ||
| 29.07. | PolyPid rises as lead product granted FDA priority review | 2 | Seeking Alpha | ||
| 29.07. | PolyPid's NDA For D-PLEX100 Receives FDA Priority Review, Stock Up | 1 | RTTNews | ||
| 29.07. | PolyPid Ltd.: PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX100 | 499 | GlobeNewswire (Europe) | PDUFA target action date of November 28, 2026, approximately one quarter ahead of Company's previously communicated guidance FDA identified no Filing review issues Acceptance triggers $15 million... ► Artikel lesen | |
| 29.07. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 22.07. | H.C. Wainwright reiterates Buy on PolyPid stock, $13 target | 3 | Investing.com | ||
| 21.07. | PolyPid, Azurity Pharmaceuticals Agree to Exclusive Commercial Partnership in US and Canada | 6 | Contract Pharma | ||
| 21.07. | PolyPid Partners With Azurity In D-PLEX100 Commercialization Deal Worth Over $320 Million | 1 | pulse2.com | ||
| 21.07. | PolyPid signs $320M deal with Azurity for D-PLEX100 in U.S., Canada | 4 | Investing.com | ||
| 21.07. | PolyPid Ltd.: PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX100 in the U.S. and Canada | 335 | GlobeNewswire (Europe) | PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to... ► Artikel lesen | |
| 15.07. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 10.06. | PolyPid Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.06. | PolyPid Ltd.: PolyPid Completes New Drug Application Submission to FDA for D-PLEX100 | 195 | GlobeNewswire (Europe) | If approved, D-PLEX100 would address a critical unmet medical need in the prevention of surgical site infections PDUFA target action date currently planned for the first quarter of 2027 PETACH TIKVA... ► Artikel lesen | |
| 01.06. | PolyPid Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.05. | PolyPid Q1 2026 Earnings Call: Complete Transcript | 5 | Benzinga.com | ||
| 13.05. | PolyPid GAAP EPS of -$0.35 beats by $0.08 | 1 | Seeking Alpha |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,90 | -0,12 % | Milliardenverlust bei Biontech, TeamViewer hofft auf Wende, Lahontan Gold vor dem großen Ausbruch? | Willkommen zu einem heutigen Marktbericht mit 3 Aktien in unterschiedlichen Situationen! Da ist einerseits das Mainzer Vorzeigeunternehmen Biontech, das nach dem großen Corona-Boom nun mit einem massiven... ► Artikel lesen | |
| EVOTEC | 3,590 | -6,75 % | Evotec kooperiert mit Odyssey bei KI-gestützter Wirkstoffsuche | Evotec und das US-Biotechnologieunternehmen Odyssey Therapeutics haben eine Forschungs- und Entwicklungskooperation zur Entwicklung neuer Therapien gegen Autoimmun- und Entzündungserkrankungen vereinbart.... ► Artikel lesen | |
| AMGEN | 360,55 | -0,21 % | Amgen lays groundwork for new R&D center in Hyderabad | ||
| NOVAVAX | 6,940 | +0,58 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 9,450 | 0,00 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 1,218 | -0,16 % | Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,550 | 0,00 % | Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics? | ||
| DEFENCE THERAPEUTICS | 0,257 | +3,21 % | Defence Therapeutics Inc.: Defence Therapeutics Appoints Dr. Amie Phinney as President and Chief Executive Officer | Montreal, Quebec--(Newsfile Corp. - August 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| ABIVAX | 109,30 | -0,18 % | EQS-News: ABIVAX: Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod | EQS-News: ABIVAX
/ Key word(s): Regulatory Admission
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
30.07.2026 / 22:05 CET/CEST
The issuer... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,314 | +8,28 % | Biotech-Finanzierung: Kapital als Schlüssel zur erfolgreichen Entwicklung | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 0,991 | +2,40 % | PacBio im Umbruch: Klinisches Wachstum kompensiert kurzfristige Belastungen | ||
| IBIO | 1,254 | -1,42 % | iBio, Inc.: iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer | SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 76,70 | +1,27 % | Arrowhead-Aktie schießt 19% hoch - Biotech-Firma bringt die Gene zum Schweigen | Satter Kurssprung bei der Aktie von Arrowhead Pharmaceuticals am gestrigen Mittwoch. Nach äußerst vielversprechenden Phase-3-Studienergebnissen zu Plozasiran bei Patienten mit schwerer Hypertriglyceridämie... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,590 | 0,00 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| ONCO-INNOVATIONS | 0,352 | -8,22 % | Onco-Innovations Limited: Onco-Innovations Advances ONC010 Polymer Development with Identification of Non-Tin Catalyst and Provides Integrated Update |
Das Unternehmen POLYPID LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +4,62 % bei einem Aktienkurs von 4,075 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYPID LTD finden Sie auf Wallstreet Online.